Skip to main content
SpringerLink
Log in
Book cover

Drug Development, Regulatory Assessment, and Postmarketing Surveillance pp 123–133Cite as

Strategies for Improving the Efficiency of Long-Term Intervention Studies

  • Chapter

  • 71 Accesses

Part of the book series: NATO Advanced Study Institutes Series ((NSSA,volume 39))

Abstract

A number of major trials 1–10 evaluating various platelet suppressing drugs in the secondary prevention of myocardial infarction and cerebral ischemia have come to a close over the past two or three years (see Table 1). It had been the hope of many that promising drugs such as sulfinpyrazone, aspirin and dipyridamole would by now have been clearly shown to be of benefit and thus would have a considerable impact on two of the three major causes of death in the western world. Failing this, it might have been hoped they would have been shown to be of no value and hence efforts could have been redirected to other opportunities.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. P.C. Elwood, A.L. Cochrane, M.L. Burr, P.M. Sweetnam, G. Williams, E. Welsby, S.J. Hughes and R. Renton, A randomized controlled clinical trial of acetel salicylxc acid in the secondary prevention of mortality from myocardial infarction, Br Med J. 1: 436 (1974)

    Article  PubMed  CAS  Google Scholar 

  2. The Coronary Drug Project Research Group, Aspirin in coronary heart disease, J Chronic Dis. 29: 625 (1976)

    Article  Google Scholar 

  3. The Anturane Reinfarction Trial Research Group, Sulfinpyrazone in the prevention of cardiac death after myocardial infarction: the Anturane Reinfarction Trial, N Engl J Med. 298: 289 (1978)

    Article  Google Scholar 

  4. The Anturane Reinfarction Trial Research Group, Sulfinpyrazone in the prevention of sudden death after myocardial infarction, N Engl J Med. 302: 250 (1980)

    Article  Google Scholar 

  5. K. Breddin, Multicenter two-years prospective study on the prevention of secondary myocardial infarction by ASA in comparison with phenprocoumon and placebo, in “Essais controles multicentres principes et problemes”, edited by J.P. Boissel, C.R. Klimt, eds., I.N.S.E.R.M., Paris (1979)

    Google Scholar 

  6. P.C. Elwood and P.M. Sweetnam, Aspirin and secondary mortality after myocardial infarction, Lancet, ii: 1313 (1979)

    Google Scholar 

  7. Aspirin Myocardial Infarction Study Research Group, A randomized controlled trial of aspirin in persons recovered from myocardial infarction, JAMA. 243: 661 (1980)

    Article  Google Scholar 

  8. The Persantine - Aspirin Reinfarction Study Research Group, Persantine and aspirin in coronary heart disease, Circulation. 62: 449 (1980)

    Article  Google Scholar 

  9. W.S. Fields, N.A. Lemak, R.F. Frankowski and R.J. Hardy, Controlled trial of aspirin in cerebral ischemia, Stroke. 8: 301 (1977)

    Article  PubMed  CAS  Google Scholar 

  10. Canadian Cooperative Study Group, A randomized trial of aspirin and sulfinpyrazone in threatened stroke, N Engl J Med. 299: 53 (1978)

    Article  Google Scholar 

  11. Genton, M. Gent, J. Hirsh and L.A. Harker, Platelet-inhibiting drugs in the prevention of clinical thombotic disease, N Engl J Med. 293: 1174, 1236, 1296 (1975)

    Article  Google Scholar 

  12. E. Genton, H.J.M. Barrxett, W.S. Fields, M. Gent and J.C. Hoak (Study Group on Antithrombotic Therapy), Cerebral ischemia: The role of thrombosis and antithrombotic therapy, Stroke. 8: 148 (1977)

    Article  Google Scholar 

  13. D.L. Sackett, Design, measurement and analysis in clinical trials, in “Platelets, Drugs and Thrombosis”, J. Hirsh, J.F. Cade, A.S. Gallus and E. Schonbaum, eds., S Karger, Basel (1975)

    Google Scholar 

  14. J.R. Harnes, Sulfinpyrazone after myocardial infarction, N Engl J Med. 298: 1258 (1978)

    Google Scholar 

  15. S. Sherry, M. Gent, J.F. Mustard, M. McGregor, A. Lilienfeld and P. Yu, Sulfinpyrazone after myocardial infarction (C), N Engl J Med. 29. 8: 1259 (1978)

    Google Scholar 

  16. D.W. Evans, Anturane Reinfarction Trial (C), Lancet, ii: 366 (1978)

    Google Scholar 

  17. Editorial, Sulfinpyrazone and prevention of myocardial infarction, FDA Drug Bull. 8: 3 (1978)

    Google Scholar 

  18. Editorial, Sulfinpyrazone and prevention of myocardial infarction, and the prevention of death: a successful trial or another tribulation?, Br Med J. 1: 941 (1978)

    Google Scholar 

  19. Editorial, FDA says no to Anturane, Science. 208: 1130 (1980)

    Article  Google Scholar 

  20. J.D. Whisnant, The Canadian trial of aspirin and sulfinpyrazone in threatened stroke (C). N Engl J Med. 299: 953 (1978)

    Article  Google Scholar 

  21. J.E. Thompson, The Canadian trial of aspirin and sulfinpyrazone * in threatened stroke (C), N Engl J Med. 299: 954 (1978)

    Google Scholar 

  22. D.L. Sackett, The Canadian trial of aspirin and sulfinpyrazone in threatened stroke (C), N Engl J Med. 299: 955 (1978)

    Google Scholar 

  23. J.F. Kurtzke, Controversy in neurology: the Canadian study on TIA and aspirin. A critique of the Canadian TIA study (C), Ann Neurol. 5: 597 (1979)

    Article  PubMed  CAS  Google Scholar 

  24. H.J.M. Barnett, M. Gent, D.L. Sackett and D.W. Taylor, Controversy in neurology: the Canadian study on TIA and aspirin. A critique of the Canadian TIA study. Reply (C), Ann Neurol. 5: 599 (1979)

    Article  PubMed  CAS  Google Scholar 

  25. P. Armitage, Controversy in the interpretation of clinical trials, Ann Neurol. 5: 601 (1979)

    Article  PubMed  CAS  Google Scholar 

  26. A.M. Lilienfeld, Critique of “A randomized trial of aspirin and sulfinpyrazone in threatened stroke”, in “Cerebrovascular Diseases”, T.R. Price and E. Nelson, eds., Raven Press, New York (1979)

    Google Scholar 

  27. J.F. Kurtzke, Critique of the Canadian “TIA” study, in “Cerebrovascular Diseases”, T.R. Price and E. Nelson, eds., Raven Press, New York (1979)

    Google Scholar 

  28. C.H. Millikan, Does taking aspirin prevent stroke in the general population, TIA patients, completed stroke patients?, in “Drug Treatment and Prevention in Cerebrovascular Disorders”, G. Tognoni and S. Garattini eds., Elsevier/North-Holland Biomedical Press, Amsterdam (1979)

    Google Scholar 

  29. M. Gent, Recent intervention studies of platelet suppressant drugs in cerebral ischemia: Methodological aspects, in “Drug Treatment and Prevention in Cerebrovascular Disorders”, G. Tognoni and S. Garattini eds., Elsevier/North-Holland Biomedical Press, Amsterdam (1979)

    Google Scholar 

  30. J.F. Whisnant, The Canadian trial of aspirin and sulfinpyrazone in threatened stroke, Am Heart J. 99: 129 (1980)

    Article  PubMed  CAS  Google Scholar 

  31. P. Armitage, Trials of antiplatelet drugs, some methodological considerations, Rev epidem et sante publ. 27: 87 (1979)

    CAS  Google Scholar 

  32. M. Gent and D.L. Sackett, The qualification and disqualification of patients and events in long term cardiovascular clinical trials, Thromb Hemostas. 41: 123 (1979)

    CAS  Google Scholar 

  33. D.L. Sackett and M. Gent, Controversy in counting and attrib-uting events in clinical trials, N Engl J Med. 301: 1410 (1979)

    Article  PubMed  CAS  Google Scholar 

  34. D. Schwartz and J. Lellouch, Explanatory and pragmatic attitudes in therapeutic trials, J Chronic Dis. 20: 637 (1967)

    Article  PubMed  CAS  Google Scholar 

  35. R. Peto, M.C. Pike, P. Armitage, N.E. Breslow, D.R. Cox, S.V. Howard, N. Mantel, K. McPherson, J. Peto and P.G. Smith, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I: Introduction and design, Br J Cancer. 34: 585 (1976)

    Article  PubMed  CAS  Google Scholar 

  36. R. Peto, M.C. Pike, P. Armitage, N.E. Breslow, D.R. Cox, S.V. Howard, N. Mantel, K. McPherson, J. Peto and P.G, Smith, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II: Analysis and examples, Br J Cancer. 35: 1 (1977)

    Article  PubMed  CAS  Google Scholar 

  37. T.L. Simon, J.H. Ware and J.M. Stengle, Clinical trials of thrombolytic agents in myocardial infarction, Am Int Med. 79: 712 (1973)

    CAS  Google Scholar 

  38. A. Kaegi, G.F. Pineo, A.G. Shimizu, H. Trivedi, J. Hirsh and M. Gent, The role of sulfinpyrazone in the prevention of arteriovenous shunt thrombosis, Circulation. 52: 497 (1975)

    Article  PubMed  CAS  Google Scholar 

  39. Multicentre International Study, Reduction in mortality after myocardial infarction with long-term beta-adrenoceptor blockade, Br Med J. 2: 419 (1977)

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada

    Michael Gent

Authors
  1. Michael Gent
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The University of Rochester School of Medicine and Dentistry, Rochester, New York, USA

    William M. Wardell

  2. University of Padua, Verona, Italy

    Giampaolo Velo

Rights and permissions

Reprints and permissions

Copyright information

© 1981 Springer Science+Business Media New York

About this chapter

Cite this chapter

Gent, M. (1981). Strategies for Improving the Efficiency of Long-Term Intervention Studies. In: Wardell, W.M., Velo, G. (eds) Drug Development, Regulatory Assessment, and Postmarketing Surveillance. NATO Advanced Study Institutes Series, vol 39. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-4055-3_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4684-4055-3_14

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4684-4057-7

  • Online ISBN: 978-1-4684-4055-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation